battleship cruis speedboat pace
lot like earn thermo fisher highlight peer-
lead top-and-bottom line growth result impress highlight
organ growth rate came ahead expect histor
weve frame thermo fisher like battleship resili regardless
portfolio divers custom reach valu
proposit show thermo fisher drive acceler growth like
speedboat well show nimbl execut healthi end market environ
gain share custom wallet view abil thermo fisher outgrow
peer despit much larger size testament compani differenti
strategi consist execut focu high-growth area
look believ organ growth capit deploy fx
repres rel opportun thermo fisher posit ep
estim upper end guidanc organ
growth forecast screen conserv context
perform strong end market fundament manag note
guidanc assum normal purchas environ vs partial
benefit custom budget flush continu favor compani
biopharma exposur rel peer uniqu capabl area
bioproduct clinic trial logist recent acquir patheon busi
believ breadth compani offer enabl share gain
custom push organ growth toward upper end long-term
guidanc increment capit deploy toward share repurchas
would also repres upsid model current trajectori thermo fisher
exit net debt ebitda model think give
manag capac deploy final fx manag
note guidanc assum tailwind fx base averag rate
past two month period us dollar weaken reiter
ow rate rais pt recommend share
high-qual avenu gain exposur theme innov healthcar
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target
capit deploy better result
life acquisit upsid case reflect
upsid ebitda billion
thermo fisher exposur econom activ
end market could impact growth
downsid case reflect downsid
ebitda billion
lot like earn thermo fisher highlight peer-lead
top-and-bottom line growth result impress highlight organ
growth rate came ahead expect histor weve frame
thermo fisher like battleship resili regardless oper
environ given portfolio divers custom reach valu proposit
show thermo fisher drive acceler growth like speedboat well
show nimbl execut healthi end market environ gain share custom
wallet view abil thermo fisher outgrow peer despit much
larger size testament compani differenti strategi consist execut
focu high-growth area
believ compani scale execut strategi carri signific
momentum thermo fisher guidanc screen conserv us
number area believ organ growth capit deploy fx repres
rel opportun thermo fisher posit ep estim
upper end guidanc organ growth forecast screen
conserv context fourth quarter perform strong end market
fundament manag note guidanc assum normal purchas
environ vs partial benefit custom budget flush
continu favor compani biopharma exposur rel peer uniqu
capabl area bioproduct clinic trial logist recent acquir
patheon busi believ breadth compani offer enabl
share gain custom push organ growth toward upper
end long-term guidanc increment capit deploy toward
share repurchas would also repres upsid model current trajectori
thermo fisher exit net debt ebitda model think
give manag capac deploy final fx manag
note guidanc assum tailwind fx base averag rate past
two month period us dollar weaken reiter
overweight rate recommend share high-qual avenu gain exposur
theme innov healthcar
rais price target better visibl core growth
trend price target repres adj ebitda forecast
billion prior price target repres prior adj ebitda forecast
thermo fisher initi guidanc revenu ep expect
though higher base due beat compani forecast revenu
rang billion repres total revenu growth
revenu growth emb organ growth million tailwind tax
growth complet acquisit notabl patheon end market
academic/govern healthcare/clin mid-singl digit growth industri
mid- high-singl growth biopharma given solid macro condit strong
finish view organ growth guidanc conserv look thermo
fisher rais outlook year progress
mid-singl digit growth
guidanc
adj ep project rang y/i beyond
top line assumpt discuss thermo fisher expect expand oper margin
includ patheon dilut net interest expens expect
rang million y/i step due increment financ patheon
assumpt quarterli rate increas thermo fisher expect tax rate benefit
 tax reform forecast non-gaap tax rate
y/i averag dilut share outstand forecast fall rang million
includ assumpt compani repurchas million worth
share fx anticip neutral oper incom line
impact expens expect drive benefit ep
expect focu confer call relat thermo fisher
bioproduct patheon busi remind signific amount
nois relat busi custom inventori de-stock impact
bioproduct revenu hurrican caus disrupt patheon site puerto
rico importantli updat busi confirm issu
resolv
relat bioproduct follow two consecut quarter moder growth
assum lsd msd appear busi return strength
manag optimist long-term driver bioproduct market
believ custom valu proposit posit compani well specif
confer call ceo marc casper note bioproduct standpoint good
year bioproduct grew compani averag know
bullish mid- long-term prospect busi got great tailwind
macro perspect like way finish year quarter
strong growth
thermo fisher provid estim hurrican maria impact oper
puerto rico result hurrican maria manati site offlin period
time resum ship late fulli oper thermo fisher
three site island puerto rico largest patheon site manati
puerto rico base disclosur patheon prior acquisit believ
facil repres roughli patheon manufactur footprint squar feet
thermo fisher note site gener roughli million revenu annual
size impact million facil locat north coast
puerto rico total compani employe island
thermo fisher activ capit deploy highlight
patheon acquisit august thermo fisher close acquisit
patheon lead global provid high-qual drug develop deliveri solut
biopharma market addit patheon acquisit thermo fisher activ
share repurchas complet number tuck-in acquisit includ
finess solut informat quarter compani return
million sharehold dividend though surprisingli repurchas
share addit compani recent complet billion european bond
offer financ patheon acquisit reflect compani complet
acquisit affymetrix march fei co acquisit septemb
largest transact compani histori thermo fisher complet
billion capit deploy call ceo casper note thermo
fisher substanti flexibl addit attract opportun
present term free cash flow project thermo fisher gener
billion estim thermo fisher end quarter net debt ttm
ebitda near-term capit deploy focus de-lever
net debt ttm ebitda
patheon clearli excit around recent close acquisit
believ signific opportun take share win busi
improv profit asset remind billion acquisit
patheon close end august part lab product servic divis
acquisit make thermo fisher one market leader contract drug
manufactur own patheon thermo fisher believ remov element
complex suppli chain biopharma custom mani biopharma
sponsor thermo fisher largest supplier spend weve seen
debt ttm ebitda barclay thermo fisher scientif inc
cro industri industri pressur sponsor led consolid number
trust supplier choos work similarli small mid-siz biotech
compani dont capabl manufactur api drug
thermo fisher see natur cross-sel opportun compani clinic
trial logist busi given thermo fisher scale biopharma servic like
biopharma sponsor alreadi work compani clinic
trial logist patheon provid logic hand-ov clinic trial logist busi
drug manufactur thermo fisher provid pack ship servic
trial lot risk handoff clinic trial work
thermo fisher believ
industri consolid around time
addit custom also need cold chain servic thermo fisher provid
charg real value-ad servic custom thermo fisher
intend keep ad capit select franchis time continu
strategi patheon pursu stand-alon entiti
term deal model thermo fisher guid investor year
accret million ebit cost revenu synergi year
term revenu synergi million year million ebit thermo
fisher note alreadi receiv inbound request cross-sel clinic
trial logist addit thermo fisher brand credibl custom make
natur partner outsourc work aggreg share
compani see pipelin small molecul biotech
choic outsourc thermo fisher count signific amount
chang outsourc penetr could repres upsid term cost
synergi million year beyond natur area opportun public
compani cost duplic administr area procur better util
manufactur footprint would provid lot earn leverag thermo fisher see
lot under-capac site own patheon combin
factor expect push margin mid-teen compani averag
call thermo fisher provid updat deal discuss
potenti custom ceo mark casper ad term pharma servic
busi patheon custom feedback incred posit
meaning dialogu number custom busi turn
quickli term -- long process get product tech transfer thing
sort nonetheless earli feedback good revenu synergi
work alreadi achiev revenu synergi clinic trial
logist busi new pharma servic capabl happen
ramp time realli interest work go
bioproduct busi biolog proport busi well
bullish revenu growth outlook midterm busi
tax side equat think realli pharmaceut custom think
tax law chang manufactur strategi lot
older strategi put plan low tax jurisdict
advantag longer compel therefor possibl open
new opportun overtim someth continu explor
fei co believ thermo fisher acquisit fei co fit well compani
 strategi re-emphas call fei co bring market lead
platform electron microscopi microscop compani believ em
platform complement portfolio mass spectrometri certain applic
specif highlight protein identif character thermo
fisher also highlight intend drive adopt fei technolog
biopharma market compani differenti product portfolio c-level
relationship help extend fei co reach thermo fisher impress fei
manufactur facil brno czech republ plan leverag site notabl
first month ownership thermo fisher note accret
compani forecast remind fei annual
count toward organ growth
revenu billion came better estim billion
line street driven mostli better organ growth better fx
well modestli better acquisit contribut organ growth
y/i better forecast guidanc sell day
chang y/i underli trend reflect true organ trend patheon ad
lp segment growth impli revenu contribut million
stronger forecast million reassur see follow hurrican maria
disrupt puerto rico site thermo fisher guidanc model assum
site would shut though oper resum fx
tailwind revenu growth versu model
quarterli revenu mm total organ growth
store revenu growth segment
revenu contribut segment
non-gaap ep increas y/i came better
estim street compani tax rate
expect impact ep versu model oper incom
primari driver core beat came better expect
non-gaap ep growth
adjust oper incom million came expect
grew y/i oper margin declin y/i came
lower expect patheon acquisit lower margin thermo fisher
overal sg came expect revenu
 expens revenu par expect
adj oper incom mm growth
improv oper margin y/i
industri end market commentari solid importantli compani saw
reacceler biopharma end market growth y/i confer
call manag elabor trend experienc market
posit growth academ govern segment high-singl digit
repres acceler recent trend growth healthcar clinic
diagnost acceler high-singl digit driven strength season
product biomark test follow modest biopharma msd
growth growth acceler thermo fisher note biopharma
servic busi show sequenti step-up compani annual cancel
larg trial addit commentari outlook compani
bioproduct busi posit busi post strong growth
quarter notabl trend industri end market remain solid growth
mid-singl digit strength industri driven posit growth chemic
analysi well broad geograph strength
manag commentari quarter
scienc growth particularli strong led growthexcel growthstrong growthmor mutedmodest growthstrong growthbiosciencesstrong demandparticularli strong growthstrong growthstrong growthnext sequencingstrong growthteen growthl growthexcel growthstrong demandet analysi growthstrong demandanalyt appliedcontinu core weaknessindustri soft appli well lsd overallindustri continu weaknessgrew lsd appli strong order industrialgrew compani averag appli safeti channel industrialgrew compani averag appli return growth chemicalmsd growth good china growthmsd growthmass spechsd growth growth strong perform strong growthstrong growthstrong growthstrong growthchromatographystrong growthhsd growth growth strong perform strong growthstrong growthstrong growthstrong growthfei companystrong oper executionexcel oper performancedouble-digit growthstrong growthspecialti dx clinic dxsolid growth across segmentsimmuno-dx similar trend good growth immuno transplant dxsimilar trend lsd strength clinic similar trend lsd strength clinic transplant particularli stronglsd growth transplant immunodiagnosticslsd strong season busi clinic transplant dxlab product govtlsd growthlsd growth grew slightli lsd growthlsd growthlsd growthmsd growth europ chinahsd growthpharma biotechhsd growthldd growthhsd growthhsd growthmsd growthmsd growthbiopharma servicesveri strong growth growth littl slower particularli strong strong perform unfavor mix biopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesgrow well barclay thermo fisher scientif inc
life scienc solut total organ growth
estim life scienc solut revenu came expect billion
increas y/i stronger organ growth greater expect tailwind
fx drove revenu beat revenu increas y/i versu
estim follow hurrican inventori destock issu
thermo fisher bioproduct busi return strength quarter
compani bioscienc busi also call growth driver remind
acquisit affymetrix annual report organ growth
calcul quarter currenc roughli tailwind growth versu
estim tailwind segment oper incom million quarter
increas y/i adjust oper margin y/i
analyt instrument total
organ growth estim analyt instrument million stronger
expect revenu increas y/i organ currenc
tailwind quarter versu estim tailwind sequenti organ
growth flat quarter fei co includ organ growth calcul
first full quarter close septemb recent growth rate accret
segment averag fei co like help organ growth quarter thermo fisher
optimist fei co acquisit look confer call detail
integr tailwind cycl informat contribut
acquir growth approxim segment oper incom increas
y/i million vs estim oper margin
specialti diagnost organ organ growth
estim specialti diagnost result solid organ revenu
expect y/i season product strength transplant diagnost clinic
diagnost call growth driver quarter currenc tailwind
quarter versu estim tailwind report revenu improv
adjust oper incom increas y/i million
expect oper margin declin y/i
laboratori product servic organ
organ growth estim laboratori product servic segment revenu came well
expect quarter total revenu increas y/i organ
revenu increas acquisit patheon contribut segment revenu
growth versu estim commentari around patheon transact
posit look confer call detail statu integr
currenc tailwind versu estim tailwind adjust ebit
increas y/i million oper margin declin y/i
quarter compani annual clinic trial cancel
affect biopharma servic busi segment rev
increment benefit organ growth
geograph commentari strong highlight high-teen growth china
despit increasingli difficult comparison strong demand asia-pacif continu
low-teen growth driven strength china korea india thermo fisher
remain optimist china market high-teen growth expect
continu compani fastest grow market specif ceo casper note
varieti market strong includ appli diagnost healthcar
compani believ continu gain share high-prior market chines
govern includ precis medicin pharmaceut product environment
monitor compani deliv high-singl digit growth north america mid-
singl digit growth europ rest world grew low-teen
repres acceler addit thermo fisher invest
digit capabl china grow e-commerc revenu
flow oper posit million adjust net
incom capital-expenditure million repres revenu y/i thermo
fisher deploy million dividend sharehold manag
repurchas share follow august acquisit patheon estim thermo
op marginy/i growthldd growthlow-teensldd growthldd growthhsd growthldd growthlow-teenschinahigh-teensmid-teenshigh-teensstrong yearhigh-teensmid-teenshigh-teenshigh-teensjapannorth americamsd growthlsd growthlsd growthlsd growthlsd growthhsd growtheuropemsd growthlsd growthlsd growthmsd growthmsd growthlsd growthmsd growthmsd growthrowhsd declinemsd declinelsd declinelsd declineflatflatmsd growthlow-teen barclay thermo fisher scientif inc
fisher end quarter net debt ttm ebitda near-term capit
deploy focus de-lever said believ compani flexibl
pursu acquisit modest repurchas opportun present
cffo compon trend cffo free capital-expenditure mm
flowcffo net incom barclay thermo fisher scientif inc
thermo fisher mm except ep reportedincom growth profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay thermo fisher scientif inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
